>Opinion Sous-performance réitérée, OC ajusté à 7 CHF (vs 12 CHF) - Le titre ams OSRAM est en baisse de ~10% depuis la publication T3 24 (07/11), après des objectifs 2027 ressortis ~7% en dessous des attentes au niveau de l’EBITDA, une visibilité limitée à CT (T1 25 attendu ‘faible’) et un FCF décevant (-35 M€ en excluant l’effet d’un prépaiement vs un consensus à -17 M€). Cela nous conduit à revoir en baisse nos prévisions de BPA 2026/27e de ~45/32% et notre OC à 7 C...
>Underperform rating maintained, target price adjusted to CHF 7 (vs CHF 12) - ams OSRAM’s share price has shed ~10% since the Q3 24 release (07/11), after the 2027 guidance came in ~7% short of expectations at the EBITDA level, with limited visibility in the short term (Q1 25 expected to be ‘weak’) and disappointing FCF (-€ 35m excluding the effect of a prepayment vs a consensus of -€ 17m). On this basis, we have downgraded our 2026-2027 EPS estimates by ~45/32% and c...
AMS Osram has released Q3/24 results that were in line with management's guidance. Despite a decline in y-o-y revenues, adjusted EBITDA and the adjusted EBITDA margin improved, boosted by one-off payments. Consequently, cash generation strengthened significantly. Both net debt and net leverage declined sequentially. Liquidity improved, and remains at a comfortable level. The near-term outlook is soft, given the weakness in the company's end-markets.
In today's Morning Views publication we comment on developments of the following high yield issuers: AMS Osram, Sappi, Ahlstrom, Trivium, Verisure, Rolls-Royce, Air France-KLM, Bombardier, Constellium, Cirsa, Kem One, Arxada, Borr Drilling, Maxeda, NewDay, Flora Food Group (formerly Upfield), Banijay
>Q3 2024 results above expectations on profitability - This morning, ams-OSRAM reported Q3 2024 results which were above expectations. Revenues were € 881m, in line with the consensus at € 880m (guidance € 830-930m). They were up 8% q-o-q and down 3% y-o-y. Adjusted gross margin was 29.7%, close to the consensus at 30%. Adjusted EBITDA was € 166m, i.e. an EBITDA margin of 18.8%, slightly above the consensus at € 164m and 18.6% (guidance at 17-20%). Adjusted EBIT was €...
>Q3 2024 results above expectations on profitability - This morning, ams-OSRAM reported Q3 2024 results which were above expectations. Revenues were € 881m, in line with the consensus at € 880m (guidance € 830-930m). They were up 8% q-o-q and down 3% y-o-y. Adjusted gross margin was 29.7%, close to the consensus at 30%. Adjusted EBITDA was € 166m, i.e. an EBITDA margin of 18.8%, slightly above the consensus at € 164m and 18.6% (guidance at 17-20%). Adjusted EBIT was €...
In today's Morning Views publication we comment on developments of the following high yield issuers: Air France-KLM, AMS Osram, Banijay, Ahlstrom, Sappi, Trivium, Verisure, TI Fluid Systems, Telecom Italia, Nexans, PureGym, Nokia, Ardagh Metal Beverage Packaging, Gestamp
>A fresh acceleration to worldwide semiconductor sales in August at +20.6% y-o-y (vs +18.7% in July) - Worldwide semiconductor sales in August 2024 were published by the WSTS (World Semiconductor Trade Statistics) with the usual one-month lag. On a three-month moving average, sales came to $ 53.1bn, ahead of our forecast of $ 52bn. This represents a sequential increase of 3.5% and +20.6% y-o-y, after +18.7% in July. At the regional level, sales from one year to the n...
>Nouvelle accélération de la croissance des ventes mondiales de semis en août à +20.6% yoy (vs +18.7% en juillet) - Les ventes mondiales de semiconducteurs d’août 2024 ont été publiées par WSTS (World Semiconductor Trade Statistics), avec (comme toujours) un mois de décalage. En données lissées (moyenne de 3 mois), elles ressortent à 53.1 Md$ au-dessus de notre prévision à 52 Md$. Il s’agit d’une hausse séquentielle de 3.5% et annuelle de 20.6% après 18.7% en juillet....
Last week we held our fourth ODDO BHF Iberian Forum. The event was fully virtual and took place on October 1 and 2. With 62 Iberian issuers, close to 200 institutional investors and c. 800 meetings, this is one of the largest dedicated Iberian conferences held this year. This note brings together 49 feedback documents, with 5 target price revisions (o/w 3 downward revisions) and a rating downgrade on Pharma Mar. The main subjects of debate were i/ the trend in final demand in the con...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.